Back

Agreement between mega-trials and smaller trials: a meta-research study

Kastrati, L.; Raeisi-Dehkordi, H.; Llanaj, E.; Quezada-Pinedo, H. G.; Khatami, F.; Ahanchi, N. S.; Llane, A.; Mecani, R.; Muka, T.; Ioannidis, J.

2024-05-09 epidemiology
10.1101/2024.05.09.24307122 medRxiv
Show abstract

ImportanceMega-trials can provide large-scale evidence on important questions. ObjectiveTo explore how the results of mega-trails compare to the meta-analysis results of trials with smaller sample sizes. Data SourcesClinicaltrials.gov was searched for mega-trials until 10.01.2023. PubMed was searched until June 2023 for meta-analyses incorporating the results of the eligible mega-trials. Study SelectionMega-trials were eligible if they were non-cluster non-vaccine randomized control trials (RCTs); had a sample size over 10,000; and had a peer-reviewed meta-analysis publication presenting results for the primary outcome of the mega-trials and/or all-cause mortality. Data Extraction and SynthesisFor each selected meta-analysis, we extracted results of smaller trials and mega-trials included in the summary effect estimate, and combined them separately using random effects. These estimates were used to calculate the ratio of odds ratios (ROR) between mega-trials and smaller trials in each meta-analysis. Next, the ROR were combined using random-effects. Risk of bias was extracted for each trial included in our analyses (or when not available, assessed only for mega-trials). Main Outcomes and MeasuresThe main outcomes were the summary ROR for the primary outcome and all-cause mortality between mega-trials and smaller trials. Sensitivity analyses were performed with respect to the time of publishing, masking, weight, type of intervention, and specialty. ResultsOf 120 mega-trials identified, 39 (33%) had significant benefits for the primary outcome and 18 (15%) had significant benefits for all-cause mortality for the intervention. In 35 comparisons of primary outcomes (including 85 point estimates from 69 unique mega-trials and 272 point estimatesfrom smaller trials) and 26 comparisons of all-cause mortality (including 70 point estimates from 65 unique mega-trials and 267 point estimates from smaller trials), ROR was 1.00 (95% CI, 0.97-1.04) and 1.00 (95% CI, 0.97-1.04), respectively. For the primary outcomes, smaller trials published before the mega-trials had more favorable results than the mega-trials (ROR 1.05, 95% CI, 1.01-1.10), and than the subsequent smaller trials (ROR 0.91, 95% CI, 0.85-0.96). Conclusions and RelevanceMeta-analyses of smaller studies show in general comparable results with mega-trials, but smaller trials published before the mega-trials give more favorable results than the mega-trials.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.